Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get it?

A measles booster? The shingles shot? Here's expert advice on which shots you should get—and when.By Hallie LevineDiseases ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a Phase 3 trial. Read more here.

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

And AREXVY was 94.6% effective in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease, chronic heart ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

Older adults who took the respiratory syncytial virus (RSV) vaccine Arexvy at the same time as the adjuvanted seasonal quadrivalent flu shot had an adequate immune response and tolerated it safely ...